Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti–IL-6) in multiple myeloma
Identifieur interne : 003660 ( Main/Merge ); précédent : 003659; suivant : 003661Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti–IL-6) in multiple myeloma
Auteurs : Jesús San-Miguel [Espagne] ; Joan Bladé [Espagne] ; Ofer Shpilberg [Israël] ; Sebastian Grosicki [Pologne] ; Frédéric Maloisel [France] ; Chang-Ki Min [Corée du Sud] ; Marta Polo Zarzuela [Espagne] ; Tadeusz Robak [Pologne] ; Sripada V. S. S. Prasad [Inde] ; Yeow Tee Goh [Singapour] ; Jacob Laubach [États-Unis] ; Andrew Spencer [Australie] ; María-Victoria Mateos [Espagne] ; Antonio Palumbo [Italie] ; Tom Puchalski [États-Unis] ; Manjula Reddy [États-Unis] ; Clarissa Uhlar [États-Unis] ; Xiang Qin [États-Unis] ; Helgi Van De Velde [Belgique] ; Hong Xie [États-Unis] ; Robert Z. Orlowski [États-Unis]Source :
- Blood [ 0006-4971 ] ; 2014.
Descripteurs français
- KwdFr :
- Acides boroniques (administration et posologie), Adulte d'âge moyen, Anticorps monoclonaux (administration et posologie), Bortézomib, Chromosomes humains de la paire 17, Délétion de segment de chromosome, Femelle, Humains, Immunoglobuline A (sang), Interleukine-6 (antagonistes et inhibiteurs), Melphalan (administration et posologie), Myélome multiple (génétique), Myélome multiple (mortalité), Myélome multiple (sang), Myélome multiple (traitement médicamenteux), Mâle, Prednisone (administration et posologie), Protocoles de polychimiothérapie antinéoplasique (administration et posologie), Pyrazines (administration et posologie), Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Taux de survie, Études de suivi.
- MESH :
- administration et posologie : Acides boroniques, Anticorps monoclonaux, Melphalan, Prednisone, Protocoles de polychimiothérapie antinéoplasique, Pyrazines.
- antagonistes et inhibiteurs : Interleukine-6.
- génétique : Myélome multiple.
- mortalité : Myélome multiple.
- sang : Immunoglobuline A, Myélome multiple.
- traitement médicamenteux : Myélome multiple.
- Adulte d'âge moyen, Bortézomib, Chromosomes humains de la paire 17, Délétion de segment de chromosome, Femelle, Humains, Mâle, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Taux de survie, Études de suivi.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Antibodies, Monoclonal (administration & dosage), Antineoplastic Combined Chemotherapy Protocols (administration & dosage), Boronic Acids (administration & dosage), Bortezomib, Chromosome Deletion, Chromosomes, Human, Pair 17, Disease-Free Survival, Female, Follow-Up Studies, Humans, Immunoglobulin A (blood), Interleukin-6 (antagonists & inhibitors), Male, Melphalan (administration & dosage), Middle Aged, Multiple Myeloma (blood), Multiple Myeloma (drug therapy), Multiple Myeloma (genetics), Multiple Myeloma (mortality), Prednisone (administration & dosage), Pyrazines (administration & dosage), Survival Rate.
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Boronic Acids, Melphalan, Prednisone, Pyrazines.
- administration & dosage : Antineoplastic Combined Chemotherapy Protocols.
- chemical , antagonists & inhibitors : Interleukin-6.
- chemical , blood : Immunoglobulin A, Multiple Myeloma.
- drug therapy : Multiple Myeloma.
- genetics : Multiple Myeloma.
- mortality : Multiple Myeloma.
- Aged, Aged, 80 and over, Bortezomib, Chromosome Deletion, Chromosomes, Human, Pair 17, Disease-Free Survival, Female, Follow-Up Studies, Humans, Male, Middle Aged, Survival Rate.
Abstract
Adding siltuximab to VMP did not improve CR, progression-free survival, or overall survival but improved very good partial response in MM. This suggests that the association of less than CR with long-term outcomes and the role of IL-6 in MM should be reassessed.
Url:
DOI: 10.1182/blood-2013-12-546374
PubMed: 24833354
PubMed Central: 4123433
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 001802
- to stream Pmc, to step Curation: 001662
- to stream Pmc, to step Checkpoint: 001412
- to stream PubMed, to step Corpus: 003704
- to stream PubMed, to step Curation: 003590
- to stream PubMed, to step Checkpoint: 003590
- to stream Ncbi, to step Merge: 001A38
- to stream Ncbi, to step Curation: 001A38
- to stream Ncbi, to step Checkpoint: 001A38
Links to Exploration step
PMC:4123433Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti–IL-6) in multiple myeloma</title>
<author><name sortKey="San Miguel, Jesus" sort="San Miguel, Jesus" uniqKey="San Miguel J" first="Jesús" last="San-Miguel">Jesús San-Miguel</name>
<affiliation wicri:level="1"><nlm:aff id="aff1">Centro de Investigación Medica Aplicada, Clinica Universidad de Navarra, Navarra, Spain;</nlm:aff>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Centro de Investigación Medica Aplicada, Clinica Universidad de Navarra, Navarra</wicri:regionArea>
<wicri:noRegion>Navarra</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Blade, Joan" sort="Blade, Joan" uniqKey="Blade J" first="Joan" last="Bladé">Joan Bladé</name>
<affiliation wicri:level="3"><nlm:aff id="aff2">Institut d’Investigacions Biomediques August Pi I Sunyer, Hospital Clinic I Provincial, Barcelona, Spain;</nlm:aff>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Institut d’Investigacions Biomediques August Pi I Sunyer, Hospital Clinic I Provincial, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shpilberg, Ofer" sort="Shpilberg, Ofer" uniqKey="Shpilberg O" first="Ofer" last="Shpilberg">Ofer Shpilberg</name>
<affiliation wicri:level="1"><nlm:aff id="aff3">Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel;</nlm:aff>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Sackler School of Medicine, Tel-Aviv University, Tel-Aviv</wicri:regionArea>
<wicri:noRegion>Tel-Aviv</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Grosicki, Sebastian" sort="Grosicki, Sebastian" uniqKey="Grosicki S" first="Sebastian" last="Grosicki">Sebastian Grosicki</name>
<affiliation wicri:level="1"><nlm:aff id="aff4">Oddzial Hematologiczny SPZOZ Zespol Szpitali Miejskich w Chorzowie, Chorzow, Poland;</nlm:aff>
<country xml:lang="fr">Pologne</country>
<wicri:regionArea>Oddzial Hematologiczny SPZOZ Zespol Szpitali Miejskich w Chorzowie, Chorzow</wicri:regionArea>
<wicri:noRegion>Chorzow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Maloisel, Frederic" sort="Maloisel, Frederic" uniqKey="Maloisel F" first="Frédéric" last="Maloisel">Frédéric Maloisel</name>
<affiliation wicri:level="3"><nlm:aff id="aff5">Clinique Saint Anne, Strasbourg, France;</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Clinique Saint Anne, Strasbourg</wicri:regionArea>
<placeName><region type="region">Grand Est</region>
<region type="old region">Alsace (région administrative)</region>
<settlement type="city">Strasbourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Min, Chang Ki" sort="Min, Chang Ki" uniqKey="Min C" first="Chang-Ki" last="Min">Chang-Ki Min</name>
<affiliation wicri:level="3"><nlm:aff id="aff6">Seoul St. Mary’s Hospital, Seoul, Republic of Korea;</nlm:aff>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Seoul St. Mary’s Hospital, Seoul</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Polo Zarzuela, Marta" sort="Polo Zarzuela, Marta" uniqKey="Polo Zarzuela M" first="Marta" last="Polo Zarzuela">Marta Polo Zarzuela</name>
<affiliation wicri:level="3"><nlm:aff id="aff7">Hospital Clinico San Carlos, Madrid, Spain;</nlm:aff>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Hospital Clinico San Carlos, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name>
<affiliation wicri:level="1"><nlm:aff id="aff8">Medical University of Lodz, Lodz, Poland;</nlm:aff>
<country xml:lang="fr">Pologne</country>
<wicri:regionArea>Medical University of Lodz, Lodz</wicri:regionArea>
<wicri:noRegion>Lodz</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Prasad, Sripada V S S" sort="Prasad, Sripada V S S" uniqKey="Prasad S" first="Sripada V. S. S." last="Prasad">Sripada V. S. S. Prasad</name>
<affiliation wicri:level="1"><nlm:aff id="aff9">Apollo Hospitals & Research Foundation, Hyderabad, India;</nlm:aff>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>Apollo Hospitals & Research Foundation, Hyderabad</wicri:regionArea>
<wicri:noRegion>Hyderabad</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tee Goh, Yeow" sort="Tee Goh, Yeow" uniqKey="Tee Goh Y" first="Yeow" last="Tee Goh">Yeow Tee Goh</name>
<affiliation wicri:level="1"><nlm:aff id="aff10">Singapore General Hospital, Singapore, Singapore;</nlm:aff>
<country xml:lang="fr">Singapour</country>
<wicri:regionArea>Singapore General Hospital, Singapore</wicri:regionArea>
<wicri:noRegion>Singapore</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Laubach, Jacob" sort="Laubach, Jacob" uniqKey="Laubach J" first="Jacob" last="Laubach">Jacob Laubach</name>
<affiliation wicri:level="2"><nlm:aff id="aff11">Dana Farber Cancer Institute, Boston, MA;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Dana Farber Cancer Institute, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Spencer, Andrew" sort="Spencer, Andrew" uniqKey="Spencer A" first="Andrew" last="Spencer">Andrew Spencer</name>
<affiliation wicri:level="3"><nlm:aff id="aff12">Alfred Health-Monash University, Melbourne, Australia;</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Alfred Health-Monash University, Melbourne</wicri:regionArea>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mateos, Maria Victoria" sort="Mateos, Maria Victoria" uniqKey="Mateos M" first="María-Victoria" last="Mateos">María-Victoria Mateos</name>
<affiliation wicri:level="1"><nlm:aff id="aff13">Hospital Universitario Salamanca, Salamanca, Spain;</nlm:aff>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Hospital Universitario Salamanca, Salamanca</wicri:regionArea>
<wicri:noRegion>Salamanca</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Palumbo, Antonio" sort="Palumbo, Antonio" uniqKey="Palumbo A" first="Antonio" last="Palumbo">Antonio Palumbo</name>
<affiliation wicri:level="3"><nlm:aff id="aff14">Ospedale Le Molinette, Torino, Italy;</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Ospedale Le Molinette, Torino</wicri:regionArea>
<placeName><settlement type="city">Turin</settlement>
<region type="région" nuts="2">Piémont</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Puchalski, Tom" sort="Puchalski, Tom" uniqKey="Puchalski T" first="Tom" last="Puchalski">Tom Puchalski</name>
<affiliation wicri:level="2"><nlm:aff id="aff15">Janssen Research & Development, Spring House, PA;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Janssen Research & Development, Spring House</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Reddy, Manjula" sort="Reddy, Manjula" uniqKey="Reddy M" first="Manjula" last="Reddy">Manjula Reddy</name>
<affiliation wicri:level="2"><nlm:aff id="aff15">Janssen Research & Development, Spring House, PA;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Janssen Research & Development, Spring House</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Uhlar, Clarissa" sort="Uhlar, Clarissa" uniqKey="Uhlar C" first="Clarissa" last="Uhlar">Clarissa Uhlar</name>
<affiliation wicri:level="2"><nlm:aff id="aff15">Janssen Research & Development, Spring House, PA;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Janssen Research & Development, Spring House</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Qin, Xiang" sort="Qin, Xiang" uniqKey="Qin X" first="Xiang" last="Qin">Xiang Qin</name>
<affiliation wicri:level="2"><nlm:aff id="aff15">Janssen Research & Development, Spring House, PA;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Janssen Research & Development, Spring House</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Van De Velde, Helgi" sort="Van De Velde, Helgi" uniqKey="Van De Velde H" first="Helgi" last="Van De Velde">Helgi Van De Velde</name>
<affiliation wicri:level="1"><nlm:aff wicri:cut="; and" id="aff16">Janssen Research & Development, Beerse, Belgium</nlm:aff>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Janssen Research & Development, Beerse</wicri:regionArea>
<wicri:noRegion>Beerse</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Xie, Hong" sort="Xie, Hong" uniqKey="Xie H" first="Hong" last="Xie">Hong Xie</name>
<affiliation wicri:level="2"><nlm:aff id="aff15">Janssen Research & Development, Spring House, PA;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Janssen Research & Development, Spring House</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Orlowski, Robert Z" sort="Orlowski, Robert Z" uniqKey="Orlowski R" first="Robert Z." last="Orlowski">Robert Z. Orlowski</name>
<affiliation wicri:level="2"><nlm:aff id="aff17">The University of Texas MD Anderson Cancer Center, Houston, TX</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">24833354</idno>
<idno type="pmc">4123433</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123433</idno>
<idno type="RBID">PMC:4123433</idno>
<idno type="doi">10.1182/blood-2013-12-546374</idno>
<date when="2014">2014</date>
<idno type="wicri:Area/Pmc/Corpus">001802</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001802</idno>
<idno type="wicri:Area/Pmc/Curation">001662</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001662</idno>
<idno type="wicri:Area/Pmc/Checkpoint">001412</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001412</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">003704</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003704</idno>
<idno type="wicri:Area/PubMed/Curation">003590</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003590</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003590</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003590</idno>
<idno type="wicri:Area/Ncbi/Merge">001A38</idno>
<idno type="wicri:Area/Ncbi/Curation">001A38</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001A38</idno>
<idno type="wicri:doubleKey">0006-4971:2014:San Miguel J:phase:randomized:study</idno>
<idno type="wicri:Area/Main/Merge">003660</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti–IL-6) in multiple myeloma</title>
<author><name sortKey="San Miguel, Jesus" sort="San Miguel, Jesus" uniqKey="San Miguel J" first="Jesús" last="San-Miguel">Jesús San-Miguel</name>
<affiliation wicri:level="1"><nlm:aff id="aff1">Centro de Investigación Medica Aplicada, Clinica Universidad de Navarra, Navarra, Spain;</nlm:aff>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Centro de Investigación Medica Aplicada, Clinica Universidad de Navarra, Navarra</wicri:regionArea>
<wicri:noRegion>Navarra</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Blade, Joan" sort="Blade, Joan" uniqKey="Blade J" first="Joan" last="Bladé">Joan Bladé</name>
<affiliation wicri:level="3"><nlm:aff id="aff2">Institut d’Investigacions Biomediques August Pi I Sunyer, Hospital Clinic I Provincial, Barcelona, Spain;</nlm:aff>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Institut d’Investigacions Biomediques August Pi I Sunyer, Hospital Clinic I Provincial, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shpilberg, Ofer" sort="Shpilberg, Ofer" uniqKey="Shpilberg O" first="Ofer" last="Shpilberg">Ofer Shpilberg</name>
<affiliation wicri:level="1"><nlm:aff id="aff3">Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel;</nlm:aff>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Sackler School of Medicine, Tel-Aviv University, Tel-Aviv</wicri:regionArea>
<wicri:noRegion>Tel-Aviv</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Grosicki, Sebastian" sort="Grosicki, Sebastian" uniqKey="Grosicki S" first="Sebastian" last="Grosicki">Sebastian Grosicki</name>
<affiliation wicri:level="1"><nlm:aff id="aff4">Oddzial Hematologiczny SPZOZ Zespol Szpitali Miejskich w Chorzowie, Chorzow, Poland;</nlm:aff>
<country xml:lang="fr">Pologne</country>
<wicri:regionArea>Oddzial Hematologiczny SPZOZ Zespol Szpitali Miejskich w Chorzowie, Chorzow</wicri:regionArea>
<wicri:noRegion>Chorzow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Maloisel, Frederic" sort="Maloisel, Frederic" uniqKey="Maloisel F" first="Frédéric" last="Maloisel">Frédéric Maloisel</name>
<affiliation wicri:level="3"><nlm:aff id="aff5">Clinique Saint Anne, Strasbourg, France;</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Clinique Saint Anne, Strasbourg</wicri:regionArea>
<placeName><region type="region">Grand Est</region>
<region type="old region">Alsace (région administrative)</region>
<settlement type="city">Strasbourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Min, Chang Ki" sort="Min, Chang Ki" uniqKey="Min C" first="Chang-Ki" last="Min">Chang-Ki Min</name>
<affiliation wicri:level="3"><nlm:aff id="aff6">Seoul St. Mary’s Hospital, Seoul, Republic of Korea;</nlm:aff>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Seoul St. Mary’s Hospital, Seoul</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Polo Zarzuela, Marta" sort="Polo Zarzuela, Marta" uniqKey="Polo Zarzuela M" first="Marta" last="Polo Zarzuela">Marta Polo Zarzuela</name>
<affiliation wicri:level="3"><nlm:aff id="aff7">Hospital Clinico San Carlos, Madrid, Spain;</nlm:aff>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Hospital Clinico San Carlos, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name>
<affiliation wicri:level="1"><nlm:aff id="aff8">Medical University of Lodz, Lodz, Poland;</nlm:aff>
<country xml:lang="fr">Pologne</country>
<wicri:regionArea>Medical University of Lodz, Lodz</wicri:regionArea>
<wicri:noRegion>Lodz</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Prasad, Sripada V S S" sort="Prasad, Sripada V S S" uniqKey="Prasad S" first="Sripada V. S. S." last="Prasad">Sripada V. S. S. Prasad</name>
<affiliation wicri:level="1"><nlm:aff id="aff9">Apollo Hospitals & Research Foundation, Hyderabad, India;</nlm:aff>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>Apollo Hospitals & Research Foundation, Hyderabad</wicri:regionArea>
<wicri:noRegion>Hyderabad</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tee Goh, Yeow" sort="Tee Goh, Yeow" uniqKey="Tee Goh Y" first="Yeow" last="Tee Goh">Yeow Tee Goh</name>
<affiliation wicri:level="1"><nlm:aff id="aff10">Singapore General Hospital, Singapore, Singapore;</nlm:aff>
<country xml:lang="fr">Singapour</country>
<wicri:regionArea>Singapore General Hospital, Singapore</wicri:regionArea>
<wicri:noRegion>Singapore</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Laubach, Jacob" sort="Laubach, Jacob" uniqKey="Laubach J" first="Jacob" last="Laubach">Jacob Laubach</name>
<affiliation wicri:level="2"><nlm:aff id="aff11">Dana Farber Cancer Institute, Boston, MA;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Dana Farber Cancer Institute, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Spencer, Andrew" sort="Spencer, Andrew" uniqKey="Spencer A" first="Andrew" last="Spencer">Andrew Spencer</name>
<affiliation wicri:level="3"><nlm:aff id="aff12">Alfred Health-Monash University, Melbourne, Australia;</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Alfred Health-Monash University, Melbourne</wicri:regionArea>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mateos, Maria Victoria" sort="Mateos, Maria Victoria" uniqKey="Mateos M" first="María-Victoria" last="Mateos">María-Victoria Mateos</name>
<affiliation wicri:level="1"><nlm:aff id="aff13">Hospital Universitario Salamanca, Salamanca, Spain;</nlm:aff>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Hospital Universitario Salamanca, Salamanca</wicri:regionArea>
<wicri:noRegion>Salamanca</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Palumbo, Antonio" sort="Palumbo, Antonio" uniqKey="Palumbo A" first="Antonio" last="Palumbo">Antonio Palumbo</name>
<affiliation wicri:level="3"><nlm:aff id="aff14">Ospedale Le Molinette, Torino, Italy;</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Ospedale Le Molinette, Torino</wicri:regionArea>
<placeName><settlement type="city">Turin</settlement>
<region type="région" nuts="2">Piémont</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Puchalski, Tom" sort="Puchalski, Tom" uniqKey="Puchalski T" first="Tom" last="Puchalski">Tom Puchalski</name>
<affiliation wicri:level="2"><nlm:aff id="aff15">Janssen Research & Development, Spring House, PA;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Janssen Research & Development, Spring House</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Reddy, Manjula" sort="Reddy, Manjula" uniqKey="Reddy M" first="Manjula" last="Reddy">Manjula Reddy</name>
<affiliation wicri:level="2"><nlm:aff id="aff15">Janssen Research & Development, Spring House, PA;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Janssen Research & Development, Spring House</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Uhlar, Clarissa" sort="Uhlar, Clarissa" uniqKey="Uhlar C" first="Clarissa" last="Uhlar">Clarissa Uhlar</name>
<affiliation wicri:level="2"><nlm:aff id="aff15">Janssen Research & Development, Spring House, PA;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Janssen Research & Development, Spring House</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Qin, Xiang" sort="Qin, Xiang" uniqKey="Qin X" first="Xiang" last="Qin">Xiang Qin</name>
<affiliation wicri:level="2"><nlm:aff id="aff15">Janssen Research & Development, Spring House, PA;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Janssen Research & Development, Spring House</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Van De Velde, Helgi" sort="Van De Velde, Helgi" uniqKey="Van De Velde H" first="Helgi" last="Van De Velde">Helgi Van De Velde</name>
<affiliation wicri:level="1"><nlm:aff wicri:cut="; and" id="aff16">Janssen Research & Development, Beerse, Belgium</nlm:aff>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Janssen Research & Development, Beerse</wicri:regionArea>
<wicri:noRegion>Beerse</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Xie, Hong" sort="Xie, Hong" uniqKey="Xie H" first="Hong" last="Xie">Hong Xie</name>
<affiliation wicri:level="2"><nlm:aff id="aff15">Janssen Research & Development, Spring House, PA;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Janssen Research & Development, Spring House</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Orlowski, Robert Z" sort="Orlowski, Robert Z" uniqKey="Orlowski R" first="Robert Z." last="Orlowski">Robert Z. Orlowski</name>
<affiliation wicri:level="2"><nlm:aff id="aff17">The University of Texas MD Anderson Cancer Center, Houston, TX</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Blood</title>
<idno type="ISSN">0006-4971</idno>
<idno type="eISSN">1528-0020</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antibodies, Monoclonal (administration & dosage)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (administration & dosage)</term>
<term>Boronic Acids (administration & dosage)</term>
<term>Bortezomib</term>
<term>Chromosome Deletion</term>
<term>Chromosomes, Human, Pair 17</term>
<term>Disease-Free Survival</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Immunoglobulin A (blood)</term>
<term>Interleukin-6 (antagonists & inhibitors)</term>
<term>Male</term>
<term>Melphalan (administration & dosage)</term>
<term>Middle Aged</term>
<term>Multiple Myeloma (blood)</term>
<term>Multiple Myeloma (drug therapy)</term>
<term>Multiple Myeloma (genetics)</term>
<term>Multiple Myeloma (mortality)</term>
<term>Prednisone (administration & dosage)</term>
<term>Pyrazines (administration & dosage)</term>
<term>Survival Rate</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Acides boroniques (administration et posologie)</term>
<term>Adulte d'âge moyen</term>
<term>Anticorps monoclonaux (administration et posologie)</term>
<term>Bortézomib</term>
<term>Chromosomes humains de la paire 17</term>
<term>Délétion de segment de chromosome</term>
<term>Femelle</term>
<term>Humains</term>
<term>Immunoglobuline A (sang)</term>
<term>Interleukine-6 (antagonistes et inhibiteurs)</term>
<term>Melphalan (administration et posologie)</term>
<term>Myélome multiple (génétique)</term>
<term>Myélome multiple (mortalité)</term>
<term>Myélome multiple (sang)</term>
<term>Myélome multiple (traitement médicamenteux)</term>
<term>Mâle</term>
<term>Prednisone (administration et posologie)</term>
<term>Protocoles de polychimiothérapie antinéoplasique (administration et posologie)</term>
<term>Pyrazines (administration et posologie)</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Survie sans rechute</term>
<term>Taux de survie</term>
<term>Études de suivi</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal</term>
<term>Boronic Acids</term>
<term>Melphalan</term>
<term>Prednisone</term>
<term>Pyrazines</term>
</keywords>
<keywords scheme="MESH" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Acides boroniques</term>
<term>Anticorps monoclonaux</term>
<term>Melphalan</term>
<term>Prednisone</term>
<term>Protocoles de polychimiothérapie antinéoplasique</term>
<term>Pyrazines</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Interleukine-6</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Interleukin-6</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Immunoglobulin A</term>
<term>Multiple Myeloma</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Multiple Myeloma</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Multiple Myeloma</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Myélome multiple</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Multiple Myeloma</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Myélome multiple</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Immunoglobuline A</term>
<term>Myélome multiple</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Myélome multiple</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Bortezomib</term>
<term>Chromosome Deletion</term>
<term>Chromosomes, Human, Pair 17</term>
<term>Disease-Free Survival</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Survival Rate</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Bortézomib</term>
<term>Chromosomes humains de la paire 17</term>
<term>Délétion de segment de chromosome</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Survie sans rechute</term>
<term>Taux de survie</term>
<term>Études de suivi</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><title>Key Points</title>
<p><list list-type="bullet"><list-item><p>Adding siltuximab to VMP did not improve CR, progression-free survival, or overall survival but improved very good partial response in MM.</p>
</list-item>
<list-item><p>This suggests that the association of less than CR with long-term outcomes and the role of IL-6 in MM should be reassessed.</p>
</list-item>
</list>
</p>
</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003660 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 003660 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= Main |étape= Merge |type= RBID |clé= PMC:4123433 |texte= Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti–IL-6) in multiple myeloma }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:24833354" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
This area was generated with Dilib version V0.6.33. |